<![CDATA[Five Under 5: Top Oncology Videos for the Week of 5/3]]>

Advertisement News|Articles|May 10, 2026 Five Under 5: Top Oncology Videos for the Week of 5/3 Author(s)OncLive Staff Fact checked by: Kristi Rosa Listen0:00 / 0:00 Key Takeaways Relacorilant plus nab-paclitaxel improved PFS and OS versus nab-paclitaxel in ROSELLA for platinum-resistant gynecologic cancers after bevacizumab exposure, enabling broad use without biomarker restriction. Labeling for relacorilant includes contraindication with lifesaving corticosteroid requirements and warnings for neutropenia, severe infection, adrenal insufficiency, glucocorticoid-condition exacerbation, and embryo-fetal toxicity. Nivolumab plus AVD achieved superior PFS versus brentuximab vedotin plus AVD in stage III/IV classical Hodgkin lymphoma, with low rates of grade 3/4 immune-mediated toxicity, redefining frontline standard. Daraxonrasib delivered a major interim OS advantage in previously treated RAS-mutant metastatic PDAC, with ongoing studies evaluating frontline monotherapy and combinations and confirming benefit in phase 3. Myelofibrosis management is shifting toward patient-tailored JAK inhibitor selection and sequencing, while optimal transplant timing remains unresolved despite transplant being the only potentially curative modality.SHOW MORE The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis. Advertisement Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.Here’s what you may have missed:FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC: Alexander B. Olawaiye, MDAlexander B. Olawaiye, MD, of the University of Pittsburgh School of Medicine and the University of Pittsburgh Cancer Institute, discusses the March 2026 FDA approval of relacorilant (Lifyorli) in combination with nab-paclitaxel (Abraxane) for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic treatment regimens including at least 1 bevacizumab (Avastin)-containing regimen, supported by data from the phase 3 ROSELLA trial (NCT05257408). In ROSELLA, patients who received the combination (n = 188) experienced significant improvements in progression-free survival (PFS; HR, 0.70; 95% CI, 0.54-0.91; P = .0076) and overall survival (OS; HR, 0.65; 95% CI, 0.51-0.83; P = .0004) vs nab-paclitaxel alone (n = 193). Olawaiye emphasized that the decision is particularly clinically meaningful because ROSELLA examined the combination in a non–biomarker-selected patient population, making it available to a wider group of patients vs other approvals in this space that carry biomarker constraints. The prescribing information includes a contraindication for patients requiring corticosteroids for lifesaving indications, along with warnings for neutropenia, severe infections, adrenal insufficiency, exacerbation of glucocorticoid-treated conditions, and embryo-fetal toxicity.Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma: Alex Herrera, MDAlex Herrera, MD, of City of Hope, discusses the significance of the March 2026 FDA approval of nivolumab (Opdivo) plus doxorubicin, vinblastine, and dacarbazine (AVD) for use in patients with previously untreated stage III or IV classical Hodgkin lymphoma. The decision is supported by results from the phase 3 CA209-8UT/SWOG 1826 study (NCT03907488). The trial showed that median PFS outcomes significantly favoring nivolumab plus AVD over brentuximab vedotin (Adcetris) plus AVD (HR, 0.42; 95% CI, 0.27-0.67; P < .0001), with 3-year follow-up data presented at the 2025 ASH Annual Meeting and Exposition showing a 3-year PFS rate of 91% (95% CI, 88%-93%) vs 82% (95% CI, 78%-85%; HR, 0.48; 95% CI, 0.34-0.69; P < .0001) in the nivolumab (n = 487) and brentuximab vedotin (n = 483) arms, respectively. The combination was well tolerated, with serious adverse effects (AEs) and grade 3 or 4 immune-mediated AEs occurring at rates of 39% and 2.7%, respectively, in the nivolumab arm. Herrera concluded that these data position nivolumab plus AVD as a new standard of care in the frontline setting for those with advanced-stage classical Hodgkin lymphoma.Landmark Efficacy Data With Daraxonrasib in Previously Treated Metastatic PDAC: Shubham Pant, MD, MBBSShubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses results from the phase 3 RASolute 302 trial (NCT06625320) examining daraxonrasib (RMC-6236) in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) harboring RAS mutations, including G12D, G12V, and G12R. An interim analysis revealed that daraxonrasib produced statistically significant and clinically meaningful improvements in both PFS and OS vs standard chemotherapy. Patients who received daraxonrasib achieved a median OS of 13.2 months compared with 6.7 months in those given chemotherapy (HR, 0.40; P < .0001). The agent had a manageable safety profile, and no new safety signals were observed. These data, which will be presented at the 2026 ASCO Annual Meeting, are complemented by phase 1/2 results (NCT05379985; NCT06445062) exploring daraxonrasib as monotherapy and in combination with nab-paclitaxel (Abraxane) and gemcitabine in the frontline setting. The agent is also under investigation in frontline metastatic PDAC as part of the phase 3 RASolute-303 trial (NCT07491445). Pant characterized these findings as historic and practice-changing for both academic and community oncologists—the most impactful data since the comparison of FOLFIRINOX against gemcitabine over a decade ago—and concluded that daraxonrasib marks a new era in precision medicine for PDAC.Raising Awareness for Skin Cancer in Light of Melanoma Monday: Neil D. Gross, MD, FACSNeil D. Gross, MD, FACS, of The University of Texas MD Anderson Cancer Center, discusses the importance of year-round vigilance in skin cancer prevention and education in recognition of Skin Cancer Awareness Month and Melanoma Monday. Despite widespread public health campaigns, many patients remain unaware that melanoma can be linked to ultraviolet (UV) exposure that occurred years or even decades earlier, highlighting a persistent and critical gap in public understanding of cumulative sun damage and its role in cancer development. Gross emphasized that increasing awareness of risk factors, particularly intermittent and chronic sun exposure, must be paired with education on early warning signs like changes in the size, shape, or color of moles, as early detection remains one of the most effective ways to improve outcomes, given that melanoma is significantly more treatable when identified at an early stage. He concluded that consistent sun-protective behaviors such as sunscreen use, protective clothing, and avoidance of peak UV hours are critical not only for individuals today but for safeguarding future generations, and that sustained education and behavioral change beyond awareness campaigns are needed to reduce the overall burden of skin cancer.Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis: Andrew Kuykendall, MDAndrew Kuykendall, MD, of Moffitt Cancer Center, discusses considerations for JAK inhibitor sequencing and the role of transplant in myelofibrosis, presented at the 2026 Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma meeting. Although allogeneic stem cell transplant remains the only potentially curative option for patients with myelofibrosis, its substantial morbidity and mortality make timing decisions particularly complex, as patients experiencing meaningful improvements in symptom burden, splenomegaly, and quality of life on JAK inhibitor therapy are less inclined to pursue transplant, despite that period potentially representing an optimal disease-management window for the procedure. Regarding JAK inhibitor sequencing among the 4 FDA-approved agents, Kuykendall advocated moving away from a rigid frontline/second-line framework in favor of individualizing therapy based on patient-specific needs, citing anemia management as one example where clinicians might transition from ruxolitinib (Jakafi) to momelotinib (Ojjaara) and potentially back based on symptom control. He concluded that optimal timing of transplant referral and intervention remains the biggest unanswered question in this space, and that current JAK inhibitor selection is best guided by matching the most appropriate agent to each individual patient rather than adhering to a predefined sequencing algorithm. NewsletterStay up to date on the most recent and practice-changing oncology dataSubscribe Now! Advertisement Related ContentAdvertisementADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier InterventionByCaroline SeymourMay 9th 2026The OncFive: Top Oncology Articles for the Week of 5/3ByOncLive StaffMay 9th 2026Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast CancerByAshling Wahner May 8th 2026Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic MelanomaMay 8th 2026Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhDByMike J. Pishvaian, MD, PhDMay 8th 2026 Latest CMEMultimediaCommunity Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for MelanomaYana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology SocietySeth A. Wander, MD, PhD; Girish Kunapareddy, MDView moreVirtual EventArkansas Association of Cancer Professionals2 Sessions are Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology SocietySeth A. Wander, MD, PhD; Kit Lu, MDView moreVideo19th Annual New York GU Cancers Congress®Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MDView moreIn-Person + Virtual EventGo to PER in ChicagoMay 29-31, 2026View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice SocietySeth A. Wander, MD, PhD; Kamel Abou Hussein, MDView moreVirtual EventIowa Oncology Society1 Session is Available!View moreVirtual EventKansas Society of Clinical Oncology1 Session is Available!View moreVideoA Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCRView moreVirtual EventLouisiana Oncology Society1 Session is Available!View moreVirtual EventMissouri Oncology Society1 Session is Available!View moreVideoMedical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoMedical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic ApproachesRami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MDView moreVideoTumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLCBalazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MDView moreVideoMedical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast CancerWilliam J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhDView moreVideoCases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical InsightsGail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHSView moreVideoGI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal CancerJohn H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MDView moreVideoEvolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular TestingEileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPHView moreVideoMedical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 DysregulationRebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhDView moreVideoPER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging StrategiesJonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhDView moreVideoMedical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted TherapiesVinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MSView moreVideoCases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoBreast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer TreatmentJoyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCOView moreMultimediaEvaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MDView moreMultimediaEstablishing the Rationale for ADC and ICI Combinations in TNBCVirginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCOView moreMultimediaBreaking Down the Rationale for Targeting TROP2 in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaDissecting Clinical Trial and Real-World Data for ADCs in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaExpert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DScView moreAudioBreaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MSView moreVideoCross-Disease Integration of Immunotherapy InnovationsGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoOptimizing Treatment for Biliary Tract CancersGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoBroadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular CarcinomaGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreMultimediaPER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – NursingAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCOView moreMultimediaExpert Roundtable and Panel Discussions: Current and Future Landscape of TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCOView moreAudioPractical Considerations and Future Directions for New Treatment Strategies in SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhDView moreVideoShow Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast CancerAna C. Garrido-Castro, MD; Pedram Razavi, MD, PhDView moreAudioNavigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New OptionsRahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhDView moreVideoMedical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk AssessmentJason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MDView moreMultimediaReady for Radioligand Therapy? Patient Selection and Sequencing SimplifiedJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaImaging Matters: Decoding PSMA PET for Better Decision-MakingJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaRadioligand Therapy 101: The Science Behind the StrategyJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaWorking Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary CareJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaBURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate CancerJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreVideo Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease ContinuumTina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhDView moreMultimediaCommunity Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary TeamYana G. Najjar, MD; Sapna Patel, MDView moreVideoA New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCsSandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHSView moreVideoNavigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVOSriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRSView moreVideoEnhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment StrategiesAna Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACPView moreVideo(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient OutcomesMichelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPOView more Advertisement Advertisement Trending on OncLive1Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 20262FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma 3ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention4Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer5Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer